A new era in autoimmune T1D: Translating emerging potential into clinical reality with teplizumab

Chair: Colin Dayan (GBR)

13:00 – 13:10Treating the cause: The case for immunotherapy in T1D management​​Colin Dayan (GBR)
13:10 – 13:25Defining the opportunity: The rationale for teplizumab in Stage 2 autoimmune T1DLorenzo Piemonti (ITA)
13:25 – 13:40Real-world infusion experienceJason Baker (USA)
13:40 – 14:00Expert panel discussion and Q&AAll faculty with
Natalie Bellini (USA)
  • Monday, 28 September 2026
  • 13:00 - 14:00 CEST
  • Sofia Hall